Editorial Commentary

Bendamustine plus rituximab: is it a BRIGHT idea?

Carlo Visco, Francesca Maria Quaglia, Chiara Bovo, Maria Chiara Tisi, Mauro Krampera


Flinn et al. have reported the results of the long-term follow-up for the BRIGHT trial, an international study which compared the efficacy and the safety of bendamustine plus rituximab (BR) with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) for treatment-naive patients with indolent non-Hodgkin lymphoma (iNHL) or mantle-cell lymphoma (MCL).

Download Citation